We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CEVI.ST

Price
149.00
Stock movement down
-8.60 (-5.46%)
Company name
CellaVision AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Medical Devices
Market cap
3.55B
Ent value
3.63B
Price/Sales
4.82
Price/Book
4.63
Div yield
-
Div growth
-
Growth years
-
FCF payout
35.21%
Trailing P/E
23.66
Forward P/E
18.12
PEG
-
EPS growth
8.00%
1 year return
-30.54%
3 year return
-23.78%
5 year return
-12.26%
10 year return
10.73%
Last updated: 2025-04-10

DIVIDENDS

CEVI.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.66
Price to OCF15.53
Price to FCF23.32
Price to EBITDA15.61
EV to EBITDA15.96

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.82
Price to Book4.63
EV to Sales4.93

FINANCIALS

Per share

Loading...
Per share data
Current share count23.85M
EPS (TTM)6.30
FCF per share (TTM)6.39

Income statement

Loading...
Income statement data
Revenue (TTM)737.16M
Gross profit (TTM)493.83M
Operating income (TTM)188.88M
Net income (TTM)150.21M
EPS (TTM)6.30
EPS (1y forward)8.22

Margins

Loading...
Margins data
Gross margin (TTM)66.99%
Operating margin (TTM)25.62%
Profit margin (TTM)20.38%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash137.66M
Net receivables140.95M
Total current assets393.55M
Goodwill126.06M
Intangible assets341.62M
Property, plant and equipment119.58M
Total assets983.84M
Accounts payable45.63M
Short/Current long term debt35.39M
Total current liabilities129.39M
Total liabilities215.97M
Shareholder's equity767.86M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)228.87M
Capital expenditures (TTM)76.44M
Free cash flow (TTM)152.42M
Dividends paid (TTM)53.67M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity19.56%
Return on Assets15.27%
Return on Invested Capital18.70%
Cash Return on Invested Capital18.98%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open156.20
Daily high156.20
Daily low148.00
Daily Volume8K
All-time high492.40
1y analyst estimate270.00
Beta1.23
EPS (TTM)6.30
Dividend per share-
Ex-div date6 May 2024
Next earnings date23 Apr 2025

Downside potential

Loading...
Downside potential data
CEVI.STS&P500
Current price drop from All-time high-69.74%-10.49%
Highest price drop-75.06%-56.47%
Date of highest drop19 Oct 20239 Mar 2009
Avg drop from high-27.06%-11.07%
Avg time to new high28 days12 days
Max time to new high924 days1805 days
COMPANY DETAILS
CEVI.ST (CellaVision AB) company logo
Marketcap
3.55B
Marketcap category
Mid-cap
Description
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a web-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, the company offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
Employees
228
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The European market has recently seen mixed performances, with the pan-European STOXX Europe 600 Index edging up by 0.56% amid hopes for increased government spending, although concerns over U.S. tari...
March 28, 2025
CellaVision AB (CLVSF) reports strong regional performance and strategic alliances, despite facing sales challenges in the Americas and increased operating expenses.
February 8, 2025
As global markets navigate a mixed start to the new year, with U.S. stocks experiencing both gains and declines and notable economic indicators like the Chicago PMI showing contraction, investors are ...
January 10, 2025
In a week marked by mixed performances in major U.S. stock indexes and a notable divergence between growth and value stocks, investors are keenly observing the market's shifting dynamics. Amidst recor...
December 12, 2024
CellaVision AB (CLVSF) reports a 9% organic growth and improved gross margins, despite facing headwinds in the Americas and China.
October 25, 2024
As global markets navigate shifting economic landscapes, the Swedish market has been influenced by recent monetary policy adjustments from the European Central Bank, which have sparked optimism for fu...
October 25, 2024
As global markets navigate a period of economic adjustments, the Swedish market has shown resilience amidst broader European trends influenced by interest rate cuts and cautious economic forecasts. In...
September 20, 2024
As European inflation nears the central bank's target, the pan-European STOXX Europe 600 Index has reached record highs, suggesting a favorable environment for value investors. In this context, identi...
September 5, 2024
As global markets face heightened volatility and economic uncertainties, the Swedish stock market has also experienced fluctuations, with investors closely monitoring value opportunities amid broader ...
August 6, 2024
As global markets navigate through a period marked by rising trade tensions and shifting investment trends towards value and small-cap shares, the Swedish stock market presents unique opportunities fo...
July 22, 2024
Next page